Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker development

American Journal of Translational Research

Volumn 5, Issue 1, 2013, Pages 1-14

  Vassiliadis, Efstathios ^a,b   Barascuk, Natasha ^a,b   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Atherosclerosis; Biomarkers; Collagens; Extracellular matrix; Fibrosis; Matrix metalloproteinases; Neoepitopes; Proteoglycans

Indexed keywords

BIGLYCAN; BIOLOGICAL MARKER; COLLAGEN; LUMICAN; MATRIX METALLOPROTEINASE; PROTEINASE; PROTEOCHONDROITIN SULFATE; PROTEOGLYCAN; VERSICAN;

ATHEROFIBROSIS; ATHEROSCLEROSIS; CAPPING PHENOMENON; FIBROGENESIS; FIBROSIS; HUMAN; LIVER; NONHUMAN; PATHOGENESIS; PRODUCT DEVELOPMENT; REVIEW;

EID: 84872773288     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Lochter A and Bissel MJ. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 1999; 107: 128-136.
2. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, and Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008; 10: R63
3. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, and Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995; 92: 402-406.
4. Katsuda S and Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10: 267-274.
5. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, and Duffn KL. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58: 2420-2431.
6. Galis ZS and Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
7. Friedman SL. Liver fibrosis from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53.
8. Martinez-Hernandez A and Amenta PS. The hepatic extracellular matrix. II. Ontogenesis, regeneration and cirrhosis. Virchows Arch A Pathol Anat Histopathol 1993; 423: 77-84.
9. Schuppan D. Structure of the extracellular matrix in normal and fbrotic liver: collagens and glycoproteins. Semin Liver Dis 1990; 10: 1-10.
10. Rojkind M, Giambrone MA, and Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979; 76: 710-719.
11. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G245-G249.
12. Hemmann S, Graf J, Roderfeld M, and Roeb E. Expression of MMPs and TIMPs in liver fibrosis a systematic review with special emphasis on anti-fbrotic strategies. J Hepatol 2007; 46: 955-975.
13. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffn K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, and Christiansen C. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009; 14: 181-202.
14. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, Qvist P, and Karsdal MA. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005; 3: 553-580.
15. Vassiliadis E, Barascuk N, Didangelos A, and Karsdal MA. Novel cardiac-specifc biomarkers and the cardiovascular continuum. Biomark Insights 2012; 7: 45-57.
16. Steinberg D and Witztum JL. Lipoproteins and atherogenesis. Current concepts. JAMA 1990; 264: 3047-3052.
17. Wight TN. Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9: 1-20.
18. Wight TN and Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004; 94: 1158-1167.
19. Davies MJ, Richardson PD, Woolf N, Katz DR, and Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
20. van der Wal AC, Becker AE, van der Loos CM, Tigges AJ, and Das PK. Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to infammation: a concept. Coron Artery Dis 1994; 5: 463469.
21. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, and Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990; 82: II47-II59.
22. Falk E. Dynamics in thrombus formation. Ann N Y Acad Sci 1992; 667: 204-223.
23. Lendon C, Born GV, Davies MJ, and Richardson PD. Plaque fssure: the link between atherosclerosis and thrombosis. Nouv Rev Fr Hematol 1992; 34: 27-29.
24. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, and Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375.
25. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, and Klein KP. Remodeling of coronary arteries in human and nonhuman primates. JAMA 1994; 271: 289-294.
26. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995; 76: 24C-33C.
27. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, and Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990; 82: II47-II59.
28. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, and Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990; 82: II47-II59.
29. Murray CJ and Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442.
30. Shah PK. Infammation and plaque vulnerability. Cardiovasc Drugs Ther 2009; 23: 31-40.
31. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol 2007; 18: 492-499.
32. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, and Hinnen ML. Coronary arteriographic fndings soon after non-Qwave myocardial infarction. N Engl J Med 1986; 315: 417-423.
33. Libby P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vasc Med 1998; 3: 225-229.
34. Biasucci LM, Leo M, and De Maria GL. Local and systemic mechanisms of plaque rupture. Angiology 2008; 59: 73S-76S.
35. Finet G, Ohayon J, Rioufol G, Lefoch S, Tracqui P, Dubreuil O, and Tabib A. Morphological and biomechanical aspects of vulnerable coronary plaque. Arch Mal Coeur Vaiss 2007; 100: 547-553.
36. Libby P. Infammation in atherosclerosis. Nature 2002; 420: 868-874.
37. Schroeder AP and Falk E. Pathophysiology and infammatory aspects of plaque rupture. Cardiol Clin 1996; 14: 211-220.
38. Finet G, Ohayon J, Rioufol G, Lefoch S, Tracqui P, Dubreuil O, and Tabib A. Morphological and biomechanical aspects of vulnerable coronary plaque. Arch Mal Coeur Vaiss 2007; 100: 547-553.
39. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, and Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995; 92: 402-406.
40. Prockop DJ and Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64: 403-434.
41. van der RM and Garrone R. Collagen family of proteins. FASEB J 1991; 5: 2814-2823.
42. Bonnet J, Garderes PE, Aumailley M, Moreau C, Gouverneur G, Benchimol D, Crockett R, Larrue J, and Bricaud H. Serum type III procollagen peptide levels in coronary artery disease (a marker of atherosclerosis). Eur J Clin Invest 1988; 18: 18-21.
43. Wu JJ and Eyre DR. Structural analysis of crosslinking domains in cartilage type XI collagen. Insights on polymeric assembly. J Biol Chem 1995; 270: 18865-18870.
44. Wu JJ and Eyre DR. Structural analysis of crosslinking domains in cartilage type XI collagen. Insights on polymeric assembly. J Biol Chem 1995; 270: 18865-18870.
45. Wight TN and Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004; 94: 1158-1167.
46. Wight TN and Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004; 94: 1158-1167.
47. Onda M, Ishiwata T, Kawahara K, Wang R, Naito Z, and Sugisaki Y. Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis. Exp Mol Pathol 2002; 72: 142-149.
48. Knauper V, Lopez-Otin C, Smith B, Knight G, and Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 1544-1550.
49. O'Brien KD, Lewis K, Fischer JW, Johnson P, Hwang JY, Knopp EA, Kinsella MG, Barrett PH, Chait A, and Wight TN. Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis 2004; 177: 29-35.
50. Van Wart HE and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87: 5578-5582.
51. Van Wart HE and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87: 5578-5582.
52. Murphy G. Matrix metalloproteinases and their inhibitors. Acta Orthop Scand Suppl 1995; 266: 55-60.
53. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, and Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986; 261: 2814-2818.
54. Herron GS, Werb Z, Dwyer K, and Banda MJ. Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 1986; 261: 2810-2813.
55. Hanemaaijer R, Koolwijk P, le CL, de Vree WJ, and van H, V. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993; 296: 803-809.
56. Hanemaaijer R, Koolwijk P, le CL, de Vree WJ, and van H, V. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993; 296: 803-809.
57. Herron GS, Werb Z, Dwyer K, and Banda MJ. Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 1986; 261: 2810-2813.
58. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, Shah PK, and Libby P. Infammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999; 274: 11924-11929.
59. Galis ZS, Muszynski M, Sukhova GK, SimonMorrissey E, Unemori EN, Lark MW, Amento E, and Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-189.
60. Evans CH, Georgescu HI, Lin CW, Mendelow D, Steed DL, and Webster MW. Inducible synthesis of collagenase and other neutral metalloproteinases by cells of aortic origin. J Surg Res 1991; 51: 399-404.
61. Yanagi H, Sasaguri Y, Sugama K, Morimatsu M, and Nagase H. Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis 1991; 91: 207-216.
62. Au YP, Montgomery KF, and Clowes AW. Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells. Circ Res 1992; 70: 1062-1069.
63. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994; 75: 41-54.
64. Southgate KM, Davies M, Booth RF, and Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smoothmuscle cell proliferation. Biochem J 1992; 288: 93-99.
65. Libby P and Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
66. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, and Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579.
67. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, and Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579.
68. Goetzl EJ, Banda MJ, and Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4.
69. Wight TN and Potter-Perigo S. The Extracellular Matrix: An Active or Passive Player in Fibrosis. Am J Physiol Gastrointest Liver Physiol 2011; 301: G950-G955.
70. Schuppan D, Ruehl M, Somasundaram R, and Hahn EG. Matrix as a modulator of hepatic fbrogenesis. Semin Liver Dis 2001; 21: 351-372.
71. Vassiliadis E, Veidal SS, Simonsen H, Larsen DV, Vainer B, Chen X, Zheng Q, Karsdal MA, and Leeming DJ. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 2011; 16: 426-433.
72. Vassiliadis E, Larsen DV, Clausen RE, Veidal SS, Barascuk N, Larsen L, Simonsen H, Silvestre TS, Hansen C, Overgaard T, Leeming DJ, and Karsdal MA. Measurement of CO3-610, a Potential Liver Biomarker Derived from Matrix Metalloproteinase-9 Degradation of Collagen Type III, in a Rat Model of Reversible CarbonTetrachloride-Induced Fibrosis. Biomark Insights 2011; 6: 49-58.
73. Gorrell MD. Liver fibrosis: the hepatocyte revisited. Hepatology 2007; 46: 1659-1661.
74. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol 1999; 11: 634-640.
75. Moriya K, Bae E, Honda K, Sakai K, Sakaguchi T, Tsujimoto I, Kamisoyama H, Keene DR, Sasaki T, and Sakai T. A fbronectin-independent mechanism of collagen fbrillogenesis in adult liver remodeling. Gastroenterology 2011; 140: 1653-1663.
76. Kershenobich SD and Weissbrod AB. Liver fibrosis and infammation. A review. Ann Hepatol 2003; 2: 159-163.
77. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, and Bay-Jensen AC. Novel combinations of Post-Translational Modifcation (PTM) neo-epitopes provide tissue-specifc biochemical markers--are they the cause or the consequence of the disease? Clin Biochem 2010; 43: 793-804.
78. Kagan HM. Lysyl oxidase: mechanism, regulation and relationship to liver fibrosis. Pathol Res Pract 1994; 190: 910-919.
79. Piemonte F, Petrini S, Gaeta LM, Tozzi G, Bertini E, Devito R, Boldrini R, Marcellini M, Ciacco E, and Nobili V. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2008; 23: e457-e464.
80. Kivirikko KI. Collagens and their abnormalities in a wide spectrum of diseases. Ann Med 1993; 25: 113-126.
81. Kisseleva T and Brenner DA. Fibrogenesis of parenchymal organs. Proc Am Thorac Soc 2008; 5: 338-342.
82. Strieter RM, Keeley EC, Hughes MA, Burdick MD, and Mehrad B. The role of circulating mesenchymal progenitor cells (fbrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009; 86: 1111-1118.
83. Lee Y and Friedman SL. Fibrosis in the liver: acute protection and chronic disease. Prog Mol Biol Transl Sci 2010; 97: 151-200.
84. Watanabe A, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sutterwala FS, Mahmood S, Jhandier MN, Shi Y, Flavell RA, and Mehal WZ. Infammasome-mediated regulation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1248-G1257.
85. Friedman SL. Mechanisms of hepatic fbrogenesis. Gastroenterology 2008; 134: 1655-1669.
86. Marra F, Aleff S, Galastri S, and Provenzano A. Mononuclear cells in liver fibrosis. Semin Immunopathol 2009; 31: 345-358.
87. Bilzer M, Roggel F, and Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006; 26: 1175-1186.
88. Seki E, De MS, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, and Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
89. Kolios G, Valatas V, and Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006; 12: 7413-7420.
90. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, and Gores GJ. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-1198.
91. Fischer R, Cariers A, Reinehr R, and Haussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 2002; 123: 845-861.
92. Shi J, Hao JH, Ren WH, Zhu JR, Wang SY, and Xie YB. Pathogenesis of liver fibrosis in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2009; 17: 443-445.
93. Bhunchet E and Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood fow. Hepatology 1993; 18: 1450-1458.
94. Thabut D and Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010; 53: 976-980.
95. DeLeve LD, Wang X, and Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008; 48: 920-930.
96. DeLeve LD. Hepatic microvasculature in liver injury. Semin Liver Dis 2007; 27: 390-400.
97. Hemmann S, Graf J, Roderfeld M, and Roeb E. Expression of MMPs and TIMPs in liver fibrosis a systematic review with special emphasis on anti-fbrotic strategies. J Hepatol 2007; 46: 955-975.
98. Benyon RC and Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373-384.
99. Amalinei C, Caruntu ID, Giusca SE, and Balan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 2010; 51: 215-228.
100. Skjot-Arkil H, Clausen RE, Nguyen QH, Wang Y, Zheng Q, Martinez FJ, Hogaboam CM, Han M, Klickstein LB, Larsen MR, Nawrocki A, Leeming DJ, and Karsdal MA. Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm Med 2012; 12: 34
101. Skjot-Arkil H, Schett G, Zhang C, Larsen DV, Wang Y, Zheng Q, Larsen MR, Nawrocki A, BayJensen AC, Henriksen K, Christiansen C, Alexandersen P, Leeming DJ, and Karsdal MA. Investigation of two novel biochemical markers of infammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol 2012; 30: 371-379.
102. Veidal SS, Karsdal MA, Vassiliadis E, Nawrocki A, Larsen MR, Nguyen QH, Hagglund P, Luo Y, Zheng Q, Vainer B, and Leeming DJ. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identifcation and validation of a novel biochemical marker assay. PLoS One 2011; 6: e24753
103. Segovia-Silvestre T, Reichenbach V, Fernandez-Varo G, Vassiliadis E, Barascuk N, MoralesRuiz M, Karsdal MA, and Jimenez W. Circulating CO3-610, a degradation product of collagen III, closely refects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair 2011; 4: 19
104. Barascuk N, Vassiliadis E, Larsen L, Wang J, Zheng Q, Xing R, Cao Y, Crespo C, Lapret I, Sabatini M, Villeneuve N, Vilaine JP, Rasmussen LM, Register TC, and Karsdal MA. Development and validation of an enzyme-linked immunosorbent assay for the quantifcation of a specifc MMP-9 mediated degradation fragment of type III collagen--A novel biomarker of atherosclerotic plaque remodeling. Clin Biochem 2011; 44: 900-906.
105. Vassiliadis E, Veidal SS, Barascuk N, Mullick JB, Clausen RE, Larsen L, Simonsen H, Larsen DV, Bay-Jensen AC, Segovia-Silvestre T, Leeming DJ, and Karsdal MA. Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol 2011; 11: 6
106. Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, Klickstein L, Larsen MR, Qvist P, Christiansen C, Vainer B, and Karsdal MA. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fbrogenesis. Liver Int 2010; 30: 1293-1304.
107. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, and Karsdal MA. Procollagen type I N-terminal propeptide (PINP) is a marker for fbrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 2010; 3: 5
108. Skjot-Arkil H, Barascuk N, Register T, and Karsdal MA. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers. Assay Drug Dev Technol 2010; 8: 542-552.
109. Barascuk N, Vassiliadis E, Zheng Q, Wang Y, Wang W, Larsen L, Rasmussen LM, and Karsdal MA. Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Refect Pathological Extracellular Matrix Remodeling in Apolipoprotein E Knockout Mice. Biomark Insights 2011; 6: 97-106.
110. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, Zheng Q, Xing R, Cao Y, Rasmussen LM, and Karsdal MA. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010; 43: 899-904.
111. Vassiliadis E, Melholt RL, Byrjalsen I, Larsen DV, Chaturvedi R, Hosbond S, Saabye L, Diederichsen AC, Genovese F, Duffn KL, Zheng Q, Chen X, Leeming DJ, Christiansen C, and Karsdal MA. Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular-specifc serological biomarker. J Transl Med 2012; 10: 140
112. Vassiliadis E, Melholt RL, Byrjalsen I, Larsen DV, Chaturvedi R, Hosbond S, Saabye L, Diederichsen AC, Genovese F, Duffn KL, Zheng Q, Chen X, Leeming DJ, Christiansen C, and Karsdal MA. Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular-specifc serological biomarker. J Transl Med 2012; 10: 140.